Compare ENS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | LGND |
|---|---|---|
| Founded | 1991 | 1987 |
| Country | United States | United States |
| Employees | 9200 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | 2004 | 1997 |
| Metric | ENS | LGND |
|---|---|---|
| Price | $168.01 | $313.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $249.48 | ★ $350.92 |
| AVG Volume (30 Days) | ★ 422.3K | 188.0K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | ★ 3.09 | 0.31 |
| Revenue | ★ $216,125,000.00 | $141,102,000.00 |
| Revenue This Year | $3.70 | $8.68 |
| Revenue Next Year | $4.82 | $30.77 |
| P/E Ratio | ★ $51.49 | $994.29 |
| Revenue Growth | 15.85 | ★ 29.48 |
| 52 Week Low | $122.36 | $175.89 |
| 52 Week High | $244.30 | $326.63 |
| Indicator | ENS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 55.81 |
| Support Level | $154.95 | $277.97 |
| Resistance Level | $181.03 | $315.53 |
| Average True Range (ATR) | 5.34 | 10.46 |
| MACD | -0.87 | 0.47 |
| Stochastic Oscillator | 27.43 | 65.12 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.